Pot stocks fall as US DEA pushes cannabis reclassification hearing to December, ET HealthWorld

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

**** stocks fall as US DEA pushes cannabis reclassification hearing to December, ET HealthWorld

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Bengaluru: Shares of cannabis companies sank on Tuesday after the U.S. ***** Enforcement Administration (DEA) postponed its cannabis reclassification hearing to Dec. 2, after the U.S. presidential election.

The Department of Justice, which oversees the DEA, said Attorney General Merrick Garland recommended cannabis be reclassified as a Schedule three ***** instead of Schedule one earlier this year. Schedule one is reserved for drugs with a high potential for ****** and no accepted medical use.

Shares of Curaleaf and U.S.-listed shares of Canopy Growth fell over 10%, while Illinois-based Verano Holdings was down 12.9%.

The AdvisorShares Pure US Cannabis ETF dipped 9.1%, having fallen as much as 12% earlier in the session.

Canada-listed Green Thumb Industries, Tilray Brands, and Trulieve Cannabis were down 8.6%, 6% and 5% respectively.

“We believe both candidates are likely to let rescheduling advance, though we have more confidence in Kamala Harris than in Donald Trump,” said analysts at TD Cowen in a note.

Analysts also noted that the outcome would heavily depend on Trump’s choice for key positions such as Attorney General, the director of the DEA, and the Secretary of Health and Human Services, should he win.

The HHS’ National Survey on ***** Use and Health for 2023 showed that ********** is the most commonly used illicit *****, with 21.8% of people aged 12 or older, or 61.8 million people, reporting use.

Reclassifying ********** would represent a first step toward narrowing the wide policy chasm between state and federal cannabis laws.

Medical cannabis is legal in 38 states and various U.S. territories, while recreational use is permitted in 24 states and Washington, D.C.; however, it ******** federally ********.

Until then, “the extended wait for rescheduling decisions could maintain the status quo, leaving businesses to navigate a patchwork of state regulations and ongoing federal ambiguity,” said Pete Sahani chief executive officer of the cannabis hardware firm, the Blinc Group.

(Reporting by Seher Dareen in Bengaluru; Editing by Tasim Zahid)

• Published On Aug 28, 2024 at 02:12 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Download ETHealthworld App

• Get Realtime updates
• Save your favourite articles

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

Scan to download App
data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///ywAAAAAAQABAAACAUwAOw==

This is the hidden content, please

• Sign In
• or
• Sign Up

#**** #stocks #fall #DEA #pushes #cannabis #reclassification #hearing #December #HealthWorld

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up